Application of lycium barbarum polysaccharide in preparation of drugs for preventing and treating intestinal flora and metabolic disorder

Abstract

This invention provides the application of Lycium barbarum polysaccharide (LBP) in the preparation of drugs for the prevention or treatment of intestinal flora and metabolic disorders. Research results show that LBP can significantly improve cisplatin-induced intestinal microbiota and metabolic disorders in rats, manifested by a significant reduction in CDDP-induced serum AST and ALT levels, and improvement in the degree of liver tissue lesions. Furthermore, LBP did not exhibit toxicity in rats. LBP enhanced the diversity and richness of the gut microbiota, restored the structure of dominant symbiotic bacteria, inhibited the proliferation of potentially pathogenic bacteria, and promoted the enrichment of functional bacteria related to SCFAs generation. LBP also restored abnormal metabolism in branched-chain amino acid and aromatic amino acid metabolism, one-carbon metabolism, and lipid metabolism. This invention provides a theoretical basis for the application of natural active polysaccharides in the prevention and treatment of intestinal microbiota and metabolic disorders.

Description

Technical Field

[0001] This invention relates to the field of natural extracts and drug development, specifically to the application of Lycium barbarum polysaccharides in the preparation of drugs for preventing and treating intestinal flora and metabolic disorders. Background Technology

[0002] Cisplatin (CDDP) was the first drug used to treat 40%-80% of malignant tumors in humans, including ovarian cancer, cervical cancer, testicular cancer, head and neck cancer, non-small cell lung cancer, and many other solid tumors. CDDP itself is chemically inert and enters cells with the assistance of the copper transporter CTR1 and organic cation transporters. It is then slowly hydrolyzed into two strongly electrophilic positively charged reagents, which interact with various biomolecules through nucleophilic coordination or charge-charge interactions, such as cysteine, glutathione, nucleotides in DNA and RNA, and sulfur- and nitrogen-containing donors like histidine residues in proteins and peptides. Therefore, the main mechanism by which CDDP inhibits cancer cells is by binding to the N7 position of guanine and adenine in DNA, forming Pt-DNA adducts, leading to DNA double-strand deformation or breakage, thereby inhibiting DNA replication and transcription. However, during this treatment process, CDDP also causes toxic side effects on normal cells, as well as inherent and acquired resistance in normal tissues, greatly limiting its application. With in-depth experimental research and clinical application, it has been discovered that CDDP can cause more than 40 toxic side effects, including nephrotoxicity, gastrointestinal toxicity, ototoxicity, neurotoxicity, hematologic toxicity, cardiotoxicity, and hepatotoxicity. Furthermore, increasing evidence suggests that CDDP not only acts directly on target organs but can also disrupt gut microbiota homeostasis, triggering a series of secondary pathological changes. Therefore, developing drugs that can prevent or treat gut microbiota and metabolic disorders while reducing the toxic side effects of CDDP is of great research value. Natural polysaccharides possess advantages such as wide availability, low toxicity, structural diversity, resistance to drug resistance, diverse biological activities, and easy biodegradability. Research on their biological activities has been extensively linked to human health and disease treatment. Numerous studies have shown that polysaccharides can improve the toxic side effects of CDDP (caused by cancer) and have no limiting effect on its anticancer activity. Lycium barbarum polysaccharides (…) Lycium barbarum L Lycium barbarum polysaccharide (LBP) is one of the main active ingredients in Lycium barbarum, possessing various pharmacological effects such as immunomodulation, antioxidation, anti-inflammation, and organ protection. Studies have shown that LBP can regulate imbalanced gut microbiota and its metabolites, thereby alleviating intestinal inflammation. Simultaneously, LBP exhibits significant pharmacological activity in kidney protection and can improve metabolic disorders. Therefore, this invention establishes a rat model of CDDP-induced gut microbiota and metabolic disorders to explore the preventive / therapeutic effects of LBP on CDDP-induced gut microbiota and metabolic disorders through pharmacodynamic evaluation and changes in gut microbiota and metabolites. This provides a theoretical basis for the further development and application of LBP in the prevention / treatment of gut microbiota and metabolic disorders, and offers new insights into the research of natural polysaccharides for the prevention and treatment of gut microbiota and metabolic disorders. Summary of the Invention

[0003] The purpose of this invention is to provide the application of Lycium barbarum polysaccharides in the preparation of drugs for preventing and treating intestinal flora and metabolic disorders, and to provide a natural drug for preventing and treating intestinal flora and metabolic disorders, so as to solve the problems of limited efficacy and insufficient safety of existing drugs. To achieve the above objectives, the present invention adopts the following technical solution: Application of Lycium barbarum polysaccharides in the preparation of drugs for the prevention or treatment of intestinal flora and metabolic disorders. In the aforementioned applications, the gut microbiota and metabolic disorders were induced by cisplatin. In the aforementioned application, the wolfberry polysaccharide is prepared by the following method: wolfberry is depigmented and then a polysaccharide extract is prepared by hot water extraction. Subsequently, the extract is subjected to deproteinization, dialysis, alcohol precipitation and freeze drying to obtain crude polysaccharide. The crude polysaccharide is further purified by DEAE-52 cellulose ion exchange column chromatography to obtain purified wolfberry polysaccharide. In the aforementioned applications, the wolfberry polysaccharide is composed of five monosaccharides: glucose, galactose, xylose, mannose, and rhamnose. In the aforementioned applications, the dosage of Lycium barbarum polysaccharide was 100-600 mg / kg. In the aforementioned applications, the drug is administered orally. A drug for the prevention or treatment of gut microbiota and metabolic disorders, the medicinal ingredient of which contains Lycium barbarum polysaccharides. Compared with the prior art, the beneficial effects of the present invention are: This invention proposes for the first time the application of Lycium barbarum polysaccharide (LBP) in the preparation of drugs for the prevention or treatment of intestinal flora and metabolic disorders. Research results show that LBP exhibits good biocompatibility, and its intervention can significantly alleviate cisplatin-induced intestinal flora and metabolic disorders in a dose-dependent manner. Specifically, it significantly reduces serum AST and ALT levels and improves CDDP-induced liver tissue pathological damage, demonstrating good safety. LBP enhances the diversity and richness of the gut microbiota, restores the structure of dominant symbiotic communities, inhibits the proliferation of potentially pathogenic bacteria, and promotes the enrichment of functional communities related to SCFAs generation. LBP also restores abnormal metabolism in branched-chain amino acid and aromatic amino acid metabolism, one-carbon metabolism, and lipid metabolism. In summary, Lycium barbarum polysaccharide, as a naturally derived bioactive substance, possesses advantages such as high safety, low toxicity, and multi-target synergistic regulation, showing good application potential and development prospects in the prevention and treatment of intestinal flora and metabolic disorders. This invention focuses on the effect of Lycium barbarum polysaccharide LBP on improving CDDP-induced intestinal flora and metabolic disorders, providing data support for finding safe and effective natural drugs to treat intestinal flora and metabolic disorders. Attached Figure Description Figure 1 These are the results of liver function index detection in rats after intervention with different doses of LBP (A, B, and C represent the expression levels of AST and ALT in rat liver and the AST / ALT ratio, respectively). Figure 2 These are the HE staining results of rat liver tissue after CDDP treatment (black arrow: indicates hepatic sinusoidal dilation and congestion; yellow arrow: indicates cell swelling). Figure 3 The results of liver function index testing to assess the safety of Lycium barbarum polysaccharide LBP (A and B represent the expression levels of ALT and AST in rat liver, respectively). Figure 4 The results of HE staining of liver tissue were used to assess the safety of Lycium barbarum polysaccharide LBP. Figure 5 This is a result of the compositional characteristics of the rat gut microbiota at the phylum level; Figure 6 These are the results of the analysis of the composition and structure of the rat gut microbiota; Figure 7 These are the results of differential metabolite enrichment analysis; Figure 8 These are the results of differential metabolic lipid enrichment analysis. Detailed Implementation Example 1: Take Lycium barbarum polysaccharides, add common excipients for tablets, capsules, pills, or granules, and prepare them into tablets, capsules, pills, or granules using conventional methods. Dosage and administration: Oral administration. The dosage of Lycium barbarum polysaccharides is 300–600 mg / kg (body weight) for the treatment of CDDP-induced intestinal flora and metabolic disorders. Example 2: Take Lycium barbarum polysaccharides, add common excipients for tablets, capsules, pills, or granules, and prepare them into tablets, capsules, pills, or granules using conventional methods. Dosage and administration: Oral administration. The dosage of Lycium barbarum polysaccharides is 100–300 mg / kg (body weight) for the prevention or improvement of intestinal flora and metabolic disorders. Experimental example: 1. Animal grouping: Six-week-old male Sprague-Dawley rats were acclimatized for one week before the start of the experiment. After the acclimatization period, 56 male rats were randomly divided into 7 groups of 8 rats each: blank control group (CON), model group (CDDP), low, medium and high dose LBP groups (LBP-100, LBP-400, LBP-600), positive control group (AMI), and LBP blank treatment group (LBP-max). 2. Dosing regimen: During the experiment, the CON group received an equal volume of saline via gavage every morning, except for days 7 and 8 when an equal volume of saline was injected intraperitoneally, followed by another equal volume of saline via gavage 2 hours later. The CDDP group received an equal volume of saline via gavage every morning, except for days 7 and 8 when a 7.5 mg / kg CDDP solution was injected intraperitoneally, followed by another equal volume of saline via gavage 2 hours later. Different concentrations of LBP intervention groups (LBP-100, LBP-400, and LBP-600) received LBP at a dose of 10 mg / mL every morning. The patients were administered LBP solution by gavage at doses of 100 mg / kg, 400 mg / kg, and 600 mg / kg, respectively. On days 7 and 8, they received an intraperitoneal injection of 7.5 mg / kg CDDP solution, followed by LBP solution by gavage 2 hours later. The AMI group received the same volume of normal saline by gavage every morning, with an injection of 7.5 mg / kg CDDP solution only on days 7 and 8, followed by an injection of 200 mg / kg amifostine solution 2 hours later. The LBP-max group received 600 mg / kg LBP solution by gavage every morning until sampling. On day 10 of the experiment, the rats were euthanized and relevant samples were collected immediately. Explanation of Abbreviations English abbreviations Full English name Chinese CDDP Cisplatin Cisplatin AST Aspartate aminotransferase Aspartate aminotransferase ALT Alanine aminotransferase alanine aminotransferase HE Hematoxylin-eosin staining Hematoxylin-eosin staining LBP polysaccharides Lycium barbarum polysaccharides I. Pharmacological effects and safety evaluation of Lycium barbarum polysaccharide LBP 1.1 Experimental Materials and Methods 1.1.1 Main Reagents and Equipment Main reagents: Lycium barbarum (source: Ningxia, production batch number: 230207); cisplatin; amifostine; AST, ALT, and ELISA kits; hematoxylin-eosin kit; xylene. Main equipment: analytical balance, multi-functional microplate reader, low-temperature high-speed centrifuge, pure water system, microplate incubator, inverted microscope, cryostat, handheld vortex mixer, ultra-low temperature freezer, 4℃ freezer. 1.1.2 Preparation of Lycium barbarum polysaccharides After decolorizing the raw material, a polysaccharide extract was prepared by hot water extraction. The crude polysaccharide was then obtained by deproteinization, dialysis, alcohol precipitation and freeze drying. The crude polysaccharide was further purified by DEAE-52 cellulose ion exchange column chromatography to obtain purified LBP. The total sugar content of the LBP was determined by the phenol-sulfuric acid method, and the calculated total sugar content was 81.95 ± 1.6%. Furthermore, the monosaccharide composition and content of the LBP were determined by pre-column derivatization with 1-phenyl-3-methyl-5-pyrazolone and high-performance liquid chromatography, indicating that the LBP mainly consisted of five monosaccharides: glucose (60.84%), galactose (18.93%), xylose (17.28%), mannose (1.60%), and rhamnose (1.35%). 1.1.3 Rat blood and tissue collection After weighing, the rats were euthanized, and blood was collected by enucleation. Blood was collected in centrifuge tubes containing heparin sodium anticoagulant and in centrifuge tubes without anticoagulant. After standing, the blood was centrifuged, and the plasma and serum supernatant were collected and stored at −80°C. After removing the kidney and rinsing it with physiological saline, it was divided into two parts. One part was immediately flash-frozen in liquid nitrogen and then stored in a freezer at -80°C. The other part was placed in paraformaldehyde and stored at 4°C for later use. 1.1.4 Determination of Liver and Kidney Function Indicators in Rats The collected plasma and serum were thawed from a -80°C freezer to a 4°C freezer, and liver function indicators AST and ALT were tested according to the kit operation steps. 1.1.5 Preparation of Liver Tissue Pathological Sections Sample collection: Fresh liver tissue was collected and fixed in 4% paraformaldehyde at 4°C for 18-24 hours, and then blotted dry with filter paper; Dehydration: Liver tissue was first dehydrated with 25% sucrose PBS solution for 24 h. After the tissue settled, it was dehydrated with 30% sucrose PBS solution for 24 h. Subsequently, the dehydration process was repeated with 30% sucrose PBS solution for 24 h for one week. Embedding: Rub the embedding mold with tin foil by hand, add a portion of OCT embedding agent to the mold (be careful not to create air bubbles), place the tissue block into the mold, add more OCT embedding agent to completely embed it, and immediately place it in liquid nitrogen to solidify it. Finally, store it in a freezer at −80℃. Sectioning: Remove the embedded sample from the −80℃ freezer, place it in a cryostat for 30 minutes to recover, and then place it on the cryostat for sectioning and sample collection; Staining: First, the sections taken from −80℃ and brought to room temperature are immersed in PBS and washed 3-5 times. Then, the PBS-washed sections are immersed in hematoxylin for 1.5 min, followed by rinsing with water for 5-10 s. Next, they are immersed in differentiation solution for 1-5 s, followed by rinsing with water for 20-30 s. Then, they are immersed in blueing solution for 45 s, followed by rinsing with water for 20-30 s. Next, they are immersed in eosin solution for 1 min, followed by rinsing with water for 1-5 s. Then, they are rinsed in 75%, 80%, 95%, and 100% ethanol solutions for 2-3 s, respectively, followed by immersion in anhydrous ethanol (II) and xylene (I, II) for 1 min, respectively. Finally, neutral resin is diluted with xylene, a drop is placed on a glass slide, and the slide is sealed with a coverslip. The histopathological condition is then observed under a microscope. 1.1.6 Data Statistical Analysis All data obtained in this experiment are expressed as mean ± standard deviation (Mean ± SD). Data processing and preliminary analysis were performed using Microsoft Office 2016 software, and graphs were created using GraphPad Prism 10.6.1 software. Differences between groups were statistically tested using one-way ANOVA. P A difference < 0.05 was considered statistically significant and was indicated in the graph using symbols (such as * or #). Compared to the CON group, the difference was expressed as... * P This indicates that, compared to the CDDP group, using # P express. II. Lycium barbarum polysaccharide LBP improves CDDP-induced gut microbiota imbalance in rats 2.1 Experimental Materials and Methods 2.1.1 Main Reagents and Equipment Main reagents: AxyPrep DNA gel extraction kit (AXYGEN), TransStart Fastpfu DNA Polymerase (TransGen Biotech) Main equipment: PCR instrument, fluorometer, electrophoresis system, sequencer. 2.1.3 Sample Collection After euthanasia of rats, the cecum was rapidly isolated under sterile conditions. The contents of the cecum were collected using sterile centrifuge tubes, immediately placed in liquid nitrogen for rapid freezing, and then transferred to a -80°C freezer for storage for subsequent analysis. 2.1.4 Bioinformatics Characteristics Analysis of Rat Gut Microbiota An appropriate amount of rat fecal sample was weighed for total microbial DNA extraction, and this sample was used as a template for PCR amplification. The quality and integrity of the extracted DNA were assessed by 1% agarose gel electrophoresis. The PCR products were purified using a DNA purification system and then used to construct MiSeq sequencing libraries, followed by high-throughput sequencing on the Illumina platform. Six biological replicates were set up for each group. Bioinformatics analysis of the gut microbiota was performed by Shanghai Meiji Biopharmaceutical Technology Co., Ltd. The primer sequences used are as follows: 338F 5'-ACTCCTACGGGAGGAGGCAG-3' 806R 5'-GGACTACHVGGGTWTCTAAT-3' 2.1.5 Data Statistical Analysis The analysis of microbiome sequencing data was performed using the cloud-based bioinformatics analysis platform (www.majorbio.com) provided by Shanghai MajorBio Technology Co., Ltd. For α-diversity analysis, the Kruskal-Wallis nonparametric rank-sum test was used to compare multiple independent samples, and the Benjamini-Hochberg method was used to correct for false positive rate (FDR) in the multiple test results. In β-diversity analysis, a weighted UniFrac distance matrix was constructed based on phylogenetic relationships, and principal coordinates analysis (PCoA) was performed to assess differences in community structure among samples; simultaneously, analysis of similarities (ANOSIM) was used to statistically test differences between groups. III. Lycium barbarum polysaccharide LBP improves CDDP-induced metabolic disorders in rats 3.1 Experimental Materials and Methods 3.1.1 Main Reagents and Equipment Main reagents: chromatographic grade methanol, acetonitrile, methyl tert-butyl ether, isopropanol, formic acid and ammonium formate. Main equipment: homogenizer, shaker, high-speed refrigerated centrifuge, vortex mixer, electrophoresis apparatus, chemiluminescence / gel imaging system 3.1.2 Preparation of serum metabolic samples Sample preparation is as follows: Sampling: Remove the sample from the -80℃ freezer and gradually cool it down to 4℃; Dissolution: Take 100µL of serum sample, add 400µL of pre-cooled methanol, and vortex thoroughly for about 2 min to ensure full contact between the sample and the solvent. Then, incubate the mixture at 4℃ for 20 min to promote protein precipitation; followed by centrifugation at 4℃ and 12000rpm for 10 min. Nitrogen blowing: After centrifugation, carefully remove the supernatant and place it under a nitrogen stream to dry until the solvent is completely evaporated; Reconstitution and collection: Add 100 µL of methanol to the dried sample for reconstitution, and centrifuge again at 4℃ and 12000 rpm for 10 min. Transfer the supernatant to a liquid chromatography vial for subsequent detection and analysis. The kidney tissue was mixed with methanol and then thoroughly homogenized and dissolved using a homogenizer. The remaining steps were the same as those for preparing serum metabolic samples. 3.1.3 Preparation of Renal Lipid Metabolism Samples Sample preparation is as follows: Sampling: Remove the sample from the -80℃ freezer and gradually cool it down to 4℃; Homogenization: Accurately weigh approximately 100 mg of kidney tissue sample and add 3.0 mL of lipid extraction buffer containing internal standard (methyl tert-butyl ether: methanol = 3:1, V / V). Homogenize thoroughly using a homogenizer. Then, vortex at low temperature for 15 min to ensure complete lipid extraction. Afterward, add 200 µL of ultrapure water and vortex at low temperature for approximately 1 min to promote phase separation. Nitrogen blowing: Centrifuge the sample at 4℃ and 12000rpm for 10 min, and collect approximately 200 µL of the upper organic phase. Then collect the supernatant and blow it dry under a nitrogen stream to completely evaporate the solvent; Reconstitution and collection: Add 200 µL of lipid reconstitution solution (acetonitrile:isopropanol = 1:1, V / V) to the dried sample to fully suspend the sample. Then centrifuge at 12000 rpm for 3 min, and transfer the supernatant to a sample vial for lipid component analysis. 3.1.4 Data Statistical Analysis The LC-MS / MS chromatographic conditions were as follows: column temperature 45℃, injection volume 4 µL, flow rate 0.35 mL / min; mobile phase was (A) 5% acetonitrile in 0.1% formic acid and (B) acetonitrile. The elution program was (A) 0–1 min 95%; 1–2 min 95%–60%; 2–6.5 min 60%–20%; 6.5–11 min 20%–0%; 11–12 min 0%; 12–13 min 0%–95%; 13–15 min 95%. The LC-MS / MS mass spectrometry conditions are as follows: Mass spectrometry analysis was performed using a heated electrospray ionization (HESI) source, with scanning analysis conducted in both positive and negative ion modes. The capillary voltage was set to 3.4 kV (positive ion) and 2.0 kV (negative ion). Data acquisition employed a full-scan MSE mode with a scan time of 0.2 s and a mass scan range of 50–1000 Da. The ion source temperature was maintained at 320 °C, the sheath gas flow rate was set to 40 Arb, the auxiliary gas flow rate was 10 Arb, and the scanning gas flow rate was 1 Arb. In AcquireX acquisition mode, collision energies were sequentially set to 30 V, 60 V, and 90 V to obtain fragment information under different energy conditions. During data acquisition, the secondary mass spectrometry information of each precursor ion in the mixed sample was automatically acquired using the AcquireX mode. To monitor the instrument's operating status and assess the stability and repeatability of the analysis process, a quality control (QC) sample was prepared by mixing 30 µL of each sample. Before the formal sample analysis, 5–7 consecutive injections of the QC sample were performed to stabilize the system; subsequently, a QC sample was inserted between each set of sample analyses to continuously monitor the system stability and detection consistency throughout the data acquisition process. The final LC-MS / MS results obtained from the experiment were processed by Analysis Base File Converter, MS-DIAL, WPS, and MetaboAnalyst for format conversion, spectral analysis, data processing, difference analysis, and enrichment analysis. IV. Results and Analysis 4.1 Pharmacological effects and safety evaluation of Lycium barbarum polysaccharide LBP 4.1.1 Analysis of liver function markers in rats Different doses of LBP intervention significantly decreased the levels of AST and ALT in rat blood, as well as the AST / ALT ratio. Figure 1 As shown. Furthermore, all doses of LBP intervention reduced AST and ALT levels and the AST / ALT ratio to varying degrees, with the high-dose LBP (600 mg / kg) group showing the most significant decrease. P < 0.0001). 4.1.2 Analysis of Liver Histopathological Results After CDDP treatment, rat liver tissue showed varying degrees of damage (e.g. Figure 2 The main manifestations are pathological changes in liver tissue, such as congestion of hepatic sinusoids, swelling of hepatocytes, and disordered structure of hepatic cords. After intervention with different doses of LBP, the above-mentioned pathological changes were improved to varying degrees, the tissue structure tended to be intact, and the damage was significantly reduced. 4.1.3 Security Assessment of LBP Following continuous gavage administration of high-dose LBP, the liver function-related indicators and HE pathological results in rats were basically consistent with those in the CON group, with no significant differences observed (e.g., Figure 3 and Figure 4 This indicates that LBP did not produce significant toxic side effects on the body within this dosage range and has good in vivo safety. 4.2 Lycium barbarum polysaccharide LBP improves CDDP-induced gut microbiota imbalance in rats LBP showed a significant regulatory effect on CDDP-induced gut microbiota dysbiosis at multiple taxonomic levels (e.g., Figure 5 and Figure 6 Its main characteristics are: enhanced gut microbiota diversity and richness, restoration of dominant symbiotic microbiota structure, inhibition of the proliferation of potentially pathogenic bacteria, and promotion of the enrichment of functional microbiota related to SCFAs generation. Based on the above results, it is speculated that LBP may maintain gut microbiota homeostasis and regulate metabolic function. 4.3 Lycium barbarum polysaccharide LBP improves CDDP-induced metabolic disorders in rats CDDP-induced AKI can trigger systemic metabolic reprogramming centered on amino acid and lipid metabolism disorders, as shown in the enrichment analysis results. Figure 7 and Figure 8 As shown, LBP manifests as abnormalities in branched-chain and aromatic amino acid metabolism, imbalances in one-carbon metabolism and the antioxidant system, and metabolic abnormalities in the sphingolipid metabolism integration pathway, sphingolipid pathway, and fatty acid transport pathway. These metabolic changes, through mutual coupling, further exacerbate mitochondrial dysfunction, oxidative stress, and apoptosis, ultimately jointly promoting the occurrence and development of host metabolic disorders. Simultaneously, LBP may achieve systemic regulation of cellular functional states by modulating the amino acid metabolism-energy metabolism-oxidative stress-lipid metabolism network. This invention investigates the preventive or therapeutic effects of LBP on intestinal microbiota and metabolic disorders by constructing a CDDP-induced rat injury model. Experimental results showed that LBP significantly reduced serum AST and ALT levels in CDDP-induced rats, improved the severity of liver tissue lesions, and did not exhibit toxic effects in rats. LBP enhances gut microbiota diversity and richness, restores the structure of dominant symbiotic communities, inhibits the proliferation of potentially pathogenic bacteria, and promotes the enrichment of functional bacteria related to SCFAs generation. LBP restores abnormal metabolism in branched-chain amino acids and aromatic amino acids, one-carbon metabolism, and lipid metabolism. In summary, Lycium barbarum polysaccharides, as a naturally derived bioactive substance, possess advantages such as high safety, low toxicity, and multi-target synergistic regulation, demonstrating good application potential and development prospects in the prevention and treatment of kidney injury.

Claims

1. Application of Lycium barbarum polysaccharides in the preparation of drugs for the prevention or treatment of intestinal flora and metabolic disorders.

2. The application according to claim 1, characterized in that: The gut microbiota and metabolic disorders were induced by cisplatin.

3. The application according to claim 1 or 2, characterized in that: The wolfberry polysaccharide was prepared by the following method: wolfberry was depigmented and then polysaccharide extract was prepared by hot water extraction. The extract was then subjected to deproteinization, dialysis, alcohol precipitation and freeze drying to obtain crude polysaccharide. The crude polysaccharide was further purified by DEAE-52 cellulose ion exchange column chromatography to obtain purified wolfberry polysaccharide.

4. The application according to claim 1 or 2, characterized in that: The wolfberry polysaccharide is composed of five monosaccharides: glucose, galactose, xylose, mannose, and rhamnose.

5. The application according to claim 1 or 2, characterized in that: The dosage of Lycium barbarum polysaccharide is 100-600 mg / kg.

6. The application according to claim 1 or 2, characterized in that: The drug is administered orally.

7. A drug for preventing or treating intestinal flora and metabolic disorders, characterized in that: The medicinal components of the drug include Lycium barbarum polysaccharides.

Images